PrEvention of posttraumatic contractuRes with Ketotifen 2 (PERK 2) - protocol for a multicenter randomized clinical trial

Ayoola Ademola, Kevin A Hildebrand, Prism S Schneider, Nicholas G H Mohtadi, Neil J White, Michael J Bosse, Alexandra Garven, Richard E A Walker, Tolulope T Sajobi, Ayoola Ademola, Kevin A Hildebrand, Prism S Schneider, Nicholas G H Mohtadi, Neil J White, Michael J Bosse, Alexandra Garven, Richard E A Walker, Tolulope T Sajobi

Abstract

Background: Injuries and resulting stiffness around joints, especially the elbow, have huge psychological effects by reducing quality of life through interference with normal daily activities such as feeding, dressing, grooming, and reaching for objects. Over the last several years and through numerous research results, the myofibroblast-mast cell-neuropeptide axis of fibrosis had been implicated in post-traumatic joint contractures. Pre-clinical models and a pilot randomized clinical trial (RCT) demonstrated the feasibility and safety of using Ketotifen Fumarate (KF), a mast cell stabilizer to prevent elbow joint contractures. This study aims to evaluate the efficacy of KF in reducing joint contracture severity in adult participants with operately treated elbow fractures and/or dislocations.

Methods/design: A Phase III randomized, controlled, double-blinded multicentre trial with 3 parallel groups (KF 2 mg or 5 mg or lactose placebo twice daily orally for 6 weeks). The study population consist of adults who are at least 18 years old and within 7 days of injury. The types of injuries are distal humerus (AO/OTA type 13) and/or proximal ulna and/or proximal radius fractures (AO/OTA type 2 U1 and/or 2R1) and/or elbow dislocations (open fractures with or without nerve injury may be included). A stratified randomization scheme by hospital site will be used to assign eligible participants to the groups in a 1:1:1 ratio. The primary outcome is change in elbow flexion-extension range of motion (ROM) arc from baseline to 12 weeks post-randomization. The secondary outcomes are changes in ROM from baseline to 6, 24 & 52 weeks, PROMs at 2, 6, 12, 24 & 52 weeks and impact of KF on safety including serious adverse events and fracture healing. Descriptive analysis for all outcomes will be reported and ANCOVA be used to evaluate the efficacy KF over lactose placebo with respect to the improvement in ROM.

Discussion: The results of this study will provide evidence for the use of KF in reducing post-traumatic joint contractures and improving quality of life after joint injuries.

Trial registration: This study was prospectively registered (July 10, 2018) with ClinicalTrials.gov reference: NCT03582176.

Keywords: Contractures; DASH; Ketotifen Fumarate; OES; PCS; RCT; ROM.

Conflict of interest statement

There is no completing interest in the trial, however, the funding for the trial was obtained from the US Department of Defense. The funding body does not have any other role in this trial.

Figures

Fig. 1
Fig. 1
PERK 2 Trial Design

References

    1. Fergusson D, Hutton B, Drodge A. The Epidemiology of Major Joint Contractures: A Systematic Review of the Literature. Clin Orthop Relat Res. 2007;456:22–29. doi: 10.1007/s00198-005-0011-z.
    1. Sheps DM, Kemp KA, Hildebrand KA. Population-based incidence of proximal radial and ulnar fractures among adults in a Canadian metropolitan area. Curr Orthop Pract. 2012;23(4):364–368. doi: 10.1097/BCO.0b013e31825a2881.
    1. Sheps DM, Kemp KAR, Hildebrand KA. Population-based incidence of distal humerus fractures among adults in a Canadian urban center. Curr Orthop Pract. 2011;22(5):437–442. doi: 10.1097/BCO.0b013e318229d0b5.
    1. Sheps DM, Kemp KAR, Hildebrand KA. Elbow dislocations in a Canadian metropolitan health region: a 3-year population-based incidence study. Shoulder Elbow. 2010;2:281–286. doi: 10.1111/j.1758-5740.2010.00084.x.
    1. Sheps DM. The incidence of elbow injuries in the city of Calgary. The incidence of elbow injuries in the city of Calgary. University of Calgary. 2006.
    1. Myden C, Hildebrand K. Elbow joint contracture after traumatic injury. J Shoulder Elb Surg. 2011;20:39–44. doi: 10.1016/j.jse.2010.07.013.
    1. Doornberg JN, van Duijn PJ, Linzel D, Ring DC, Zurakowski D, Marti RK, Kloen P. Surgical treatment of intra-articular fractures of the distal part of the humerus. Functional outcome after twelve to thirty years. J Bone Joint Surg. 2007;89A:1524–1532. doi: 10.2106/00004623-200707000-00017.
    1. Forthman C, Henket M, Ring DC. Elbow dislocation with intra-articular fracture: the results of operative treatment without repair of the medial collateral ligament. J Hand Surg. 2007;32A:1200–1209. doi: 10.1016/j.jhsa.2007.06.019.
    1. Lindenhovius ALC, Jupiter JB. The Posttraumatic Stiff Elbow: A Review of the Literature. J Hand Surg. 2007;32A(10):1605–1623. doi: 10.1016/j.jhsa.2007.09.015.
    1. Cooney WP, III, Morrey BF. The Elbow and its Disorders. Philadelphia: W.B. Saunders Company; 1993. Contractures of the elbow; pp. 464–475.
    1. Monument MJ, Hart DA, Salo PT, Befus AD, Hildebrand KA. Neuroinflammatory mechanisms of connective tissue fibrosis: targeting neurogenic and mast cell contributions. Adv Wound Care. 2015;4(3):137–151. doi: 10.1089/wound.2013.0509.
    1. Monument MJ, Hart DA, Befus AD, Salo PT, Zhang M, Hildebrand KA. The mast cell stabilizer ketotifen reduces joint capsule fibrosis in a rabbit model of post-traumatic joint contractures. Inflamm Res. 2012;61:285–292. doi: 10.1007/s00011-011-0409-3.
    1. Monument MJ, Hart DA, Befus AD, Salo PT, Zhang M, Hildebrand KA. The mast cell stabilizer ketotifen fumarate lessens contracture severity and myofibroblast hyperplasia: a study of a rabbit model of posttraumatic joint contractures. J Bone Joint Surg. 2010;92A:1468–1477. doi: 10.2106/JBJS.I.00684.
    1. Schneider PS, Johal H, Zhang M, Hart D, Befus A, Salo P, Fan CY, Liang X, Hildebrand K. The dose response effect of ketotifen fumarate on post-traumatic joint contractures. Transactions of the orthopaedic research society. 2016. p. 0221.
    1. Gallant-Behm CL, Reno C, Tsao H, Hart DA. Genetic involvement in skin wound healing and scarring in domestic pigs: assessment of molecular expression patterns in (Yorkshire × red Duroc) × Yorkshire backcross animals. J Investig Dermatol. 2007;127(1):233–244. doi: 10.1038/sj.jid.5700482.
    1. Maclay WP, Crowder D, Spiro S, Turner P. Postmarketing surveillance: practical experience with ketotifen. Br Med J (Clin Res Ed) 1984;288(6421):911–914. doi: 10.1136/bmj.288.6421.911.
    1. Sullivan MJ. PCS The Pain Catastrophizing Scale User Manual 2009. PCS the pain Catastrophizing scale user manual 2009. Montreal; 2009. .
    1. Teunis Teun, Bot Arjan G. J., Thornton Emily R., Ring David. Catastrophic Thinking Is Associated With Finger Stiffness After Distal Radius Fracture Surgery. Journal of Orthopaedic Trauma. 2015;29(10):e414–e420. doi: 10.1097/BOT.0000000000000342.
    1. Vranceanu AM, Bachoura A, Weening A, Vrahas M, Smith RM, Ring D. Psychological factors predict disability and pain intensity after skeletal trauma. J Bone Joint Surg Am. 2014;96(3):e20. doi: 10.2106/JBJS.L.00479.
    1. Golkari S, Teunis T, Ring D, Vranceanu AM. Changes in depression, health anxiety, and pain Catastrophizing between enrollment and 1 month after a radius fracture. Psychosomatics. 2015;56(6):652–657. doi: 10.1016/j.psym.2015.03.008.
    1. Dawson J, Doll H, Boller I, Fitzpatrick R, Little C, Rees J, Jenkinson C, Carr AJ. The development and validation of a patient-reported questionnaire to assess outcomes of elbow surgery. J Bone Joint Surg Br. 2008;90(4):466–473. doi: 10.1302/0301-620X.90B4.20290.
    1. De Haan J, Goei H, Schep NW, Tuinebreijer WE, Patka P, den Hartog D. The reliability, validity and responsiveness of the Dutch version of the Oxford elbow score. J Orthop Surg Res. 2011;6:39. doi: 10.1186/1749-799X-6-39.
    1. Dawson J, Doll H, Boller I, Fitzpatrick R, Little C, Rees J, Carr A. Comparative responsiveness and minimal change for the Oxford elbow score following surgery. Qual Life Res. 2008;17(10):1257–1267. doi: 10.1007/s11136-008-9409-3.
    1. Iordens Gijs I T, Van Lieshout Esther M M, Schep Niels W L, De Haan Jeroen, Tuinebreijer Wim E, Eygendaal Denise, Van Beeck Ed, Patka Peter, Verhofstad Michael H J, Den Hartog Dennis. Early mobilisation versus plaster immobilisation of simple elbow dislocations: results of the FuncSiE multicentre randomised clinical trial. British Journal of Sports Medicine. 2015;51(6):531–538. doi: 10.1136/bjsports-2015-094704.
    1. Aitken SA, Jenkins PJ, Rymaszewski L. Revisiting the ‘bag of bones’. Bone Joint J. 2015;97-B(8):1132–1138. doi: 10.1302/0301-620X.97B8.35410.
    1. Fawi H, Lewis J, Rao P, Parfitt D, Mohanty K, Ghandour A. Distal third humeri fractures treated using the Synthes™ 3.5-mm extra-articular distal humeral locking compression plate: clinical, radiographic and patient outcome scores. Shoulder Elbow. 2015;7(2):104–109. doi: 10.1177/1758573214559320.
    1. Dawson J, Doll H, Boller I, Fitzpatrick R, Little C, Rees J, Carr A. Specificity and responsiveness of patient-reported and clinician-rated outcome measures in the context of elbow surgery, comparing patients with and without rheumatoid arthritis. Orthop Traumatol Surg Res. 2012;98(6):652–658. doi: 10.1016/j.otsr.2012.05.011.
    1. Beaton DE, Katz JN, Fossel AH, Wright JG, Tarasuk V, Bombardier C. Measuring the whole or the parts? Validity, reliability and responsiveness of the Disabilities of the Arm, Shoulder and Hand outcome measure in different regions of the upper extremity. J Hand Ther. 2001;14:128–146. doi: 10.1016/S0894-1130(01)80043-0.
    1. Morrey BF, Askew LJ, Chao EY. A biomechanical study of normal functional elbow motion. J Bone Joint Surg. 1981;63A(6):872–877. doi: 10.2106/00004623-198163060-00002.
    1. Toutenburg H, Rubin DB. Multiple imputation for nonresponse in surveys. Stat Papers. 1990;31(1):180.
    1. Grahnén A, Lönnebo A, Beck O, Eckernäs S-Å, Dahlström B, Lindström B. Pharmacokinetics of ketotifen after oral administration to healthy male subjects. Biopharm Drug Dispos. 1992;13(4):255–262. doi: 10.1002/bdd.2510130404.
    1. Food and Drug Administration Center for Drug Evaluation and Research . Guidance for Industry: Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials (draft) 2018.
    1. Food and Drug Administration Center for Drug Evaluation and Research . Guidance for clinical investigators, Sponsors, and IRBs: AE Reporting to IRBs – Improving Human Subject Protection. 2009.
    1. Food and Drug Administration Center for Drug Evaluation and Research . Guidance for industry and investigators: safety reporting requirements for IND, BA/BE Studies. 2013.
    1. Food and Drug Administration Center for Drug Evaluation and Research . Guidance for Industry: Safety Assessment for IND Safety Reporting (draft) 2015.
    1. Teva Canada Limited . Product Monograph. Zaditen (Ketotifen Fumarate) 2012.
    1. ICH-E2A . Guideline for industry. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. 1995.
    1. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. J Postgrad Med. 2001;47(3):199.
    1. ICH-E6 . Guidance for Industry. Good Clinical Practice: Consolidated Guidance. U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER) 1996.
    1. Canadian Association of Research Ethics Boards. Guidance on Reporting of Unexpected Problems including Adverse Events to Research Ethics Boards in Canada. 2010.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する